Advanced drug delivery systems for antithrombotic agents

Area of Science:

• Biomedical Engineering
• Pharmacology
• Vascular Biology

Background:

• Managing patients at high risk for thrombosis and hemorrhage presents challenges due to limitations of current antithrombotic pharmacotherapy.
• Existing antithrombotic agents (ATAs) have restricted utility because of inadequate pharmacokinetics and narrow therapeutic indices.
• Advanced drug delivery systems (ADDSs) are being explored to overcome these limitations.

Purpose of the Study:

• To explore the potential of ADDSs in optimizing antithrombotic agent delivery for patients at high risk of thrombosis and hemorrhage.
• To investigate how ADDSs can target drug delivery to thrombus sites and sense vascular microenvironment changes.
• To evaluate the promise of ADDSs in developing safer and more effective antithrombotic strategies.

Main Methods:

• Utilizing various nanocarriers, affinity ligands, and polymer coatings as ADDSs.
• Developing biomimetic synthetic carriers, host blood cells, and recombinant fusion proteins for targeted ATA delivery.
• Investigating ADDSs that can differentiate between hemostatic and pathological clots.

Main Results:

• Preclinical models show promising outcomes with targeted ATA delivery using novel ADDSs.
• ADDSs demonstrate potential to optimize ATA pharmacokinetics and target delivery to thrombus sites.
• The ability of ADDSs to sense pathologic vascular changes and spare hemostatic clots is highlighted.

Conclusions:

• ADDSs hold significant promise for improving the management of acute thrombotic disorders by enabling targeted, transient thromboprophylaxis.
• Further development and clinical translation of ADDSs are crucial to realize their full potential in patient care.
• A concerted effort is needed to advance ADDS technology from preclinical research to clinical application.